Drugs & Targets Health Canada approves Keytruda for gastroesophageal cancer April 26, 2024Vol.50 No.17
Drugs & Targets European Commission approves Xtandi for high-risk BCR nmHSPC April 26, 2024Vol.50 No.17
Drugs & Targets CHMP recommends approval of Opdivo combination for urothelial carcinoma April 26, 2024Vol.50 No.17
Drugs & Targets FDA revises industry guidance on biologics promotion and advertising April 26, 2024Vol.50 No.17
Conversation with The Cancer Letter “This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation April 19, 2024Vol.50 No.16By Paul Goldberg
Guest Editorial Leading a Comprehensive Cancer Center—one job or two? April 19, 2024Vol.50 No.16By George J. Weiner
Guest Editorial Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusionMinority Cancer Awareness Week April 19, 2024Vol.50 No.16By Kimlin Tam Ashing, Nadine J. Barrett, Kim F. Rhoads, Folakemi T. Odedina, Hayley S. Thompson and Camille C. R. Ragin
In Brief Andrew Smith named chair of St. Jude Diagnostic Imaging Department April 19, 2024Vol.50 No.16
In Brief Matsumoto, Wald, Woodard, Everett named to ACR leadership positions April 19, 2024Vol.50 No.16
